Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik has reported that the US Food and Drug Administration has converted the recently announced full clinical hold of Telcyta trials to a partial hold.
Subscribe to our email newsletter
This action will enable patients currently enrolled in the Assist-3 and Assist-5 trials the opportunity to continue to receive study treatments, including Telcyta in combination with chemotherapy, subject to re-consenting procedures.
Telik says it continues to work closely with the FDA in its review of Telcyta.
Telcyta is a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, Telintra, is in clinical development for myelodysplastic syndrome.